Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Doxorubicin-containing MNA · 1 trial · 1 indication
Tissue will be excised and sectioned for histologic analysis
Determination of cutaneous tolerability of arrays after application
| Arm | Type | Description |
|---|---|---|
| Doxorubicin-containing MNA - 100 µg | ACTIVE_COMPARATOR | A doxorubicin-containing array of 100 µg will be applied to subjects. |
| Placebo MNA for Training | EXPERIMENTAL | Training phase for application of arrays |
| Name | Type | Description |
|---|---|---|
| Doxorubicin-containing MNA | COMBINATION_PRODUCT | A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent |
| Placebo-containing MNA | DRUG | A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo |
Inclusion Criteria: 1. Adult males and females, 18+ years in general good health as assessed by the investigator. 2. Clinical laboratory results within the following ranges: 1. granulocytes ≥2,000/mm3 2. platelets \>50,000/mm3 3. serum creatinine ≤2X the upper limit of normal (ULN) 4. ...
Doxorubicin-containing MNA is an investigational small molecule therapy being developed by Medicus Pharma Ltd. for the treatment of basal cell carcinoma. It is a microneedle array product that delivers doxorubicin, a chemotherapy agent, directly into the skin. It is currently in Phase 1 clinical development.
Doxorubicin-containing MNA is being developed for the treatment of basal cell carcinoma, a type of skin cancer. It is intended for topical administration via microneedles. The product is investigational and has not been approved for any indication.
Doxorubicin-containing MNA is being developed by Medicus Pharma Ltd., which trades under the ticker symbol MDCX. The company is responsible for the clinical development of this investigational therapy for basal cell carcinoma.
Doxorubicin-containing MNA is in Phase 1 clinical development. The ongoing trial is an active, randomized, double-blind, active-controlled study. It is not yet approved by the FDA or any regulatory agency.
Doxorubicin-containing MNA is being evaluated in a Phase 1 trial, NCT04928222, titled 'Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II).' The trial is active but not recruiting, with an estimated enrollment of 25 participants in the United States.